# Rein Therapeutics, Inc.: overview RNTX · Nasdaq · CIK 1420565 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rntx.md) · [Financials](/companies/rntx/financials.md) · [Filings](/companies/rntx/filings.md) · [Insiders](/companies/rntx/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-350270.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-350270). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001193125-25-281622.md) | [0.0 d](/filings/0001193125-26-126385.md) | [0.0](/filings/0001193125-26-225352.md) | [0.0](/filings/0001193125-26-350270.md) | [0.0](/filings/0001193125-25-281622.md) | [0.0 d](/filings/0001193125-26-126385.md) | [0.0](/filings/0001193125-26-225352.md) | [0.0](/filings/0001193125-26-350270.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0001193125-25-281622.md) | not reported | [(0.25)](/filings/0001193125-26-225352.md) | [(0.28)](/filings/0001193125-26-350270.md) | [(0.21)](/filings/0001193125-25-281622.md) | not reported | [(0.19)](/filings/0001193125-26-225352.md) | [(0.10)](/filings/0001193125-26-350270.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0000950170-23-008767.md) | [0.0](/filings/0000950170-24-044508.md) | [0.0](/filings/0000950170-25-051566.md) | [0.0](/filings/0001193125-26-126385.md) | [0.0](/filings/0001193125-26-126385.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.89)](/filings/0000950170-23-008767.md) | [(6.02)](/filings/0000950170-24-044508.md) | [(3.42)](/filings/0000950170-25-051566.md) | [(3.51)](/filings/0001193125-26-126385.md) | [(1.96)](/filings/0001193125-26-126385.md) | | Free cash flow | $m | [(23.9)](/filings/0000950170-23-008767.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rntx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Voss Capital, LP](/funds/1730145.md) | 2026-06-30 | $5.5m | 5,261,921 | | Added +873,559 | | [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $5.4m | 5,195,000 | | Added +4,775,000 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $4.7m | 4,500,000 | | New +4,500,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.5m | 3,377,910 | | Added +2,379,389 | | [BIOS Capital Management, LP](/funds/1813845.md) | 2026-06-30 | $3.1m | 2,982,375 | | Added +1,000,000 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $3.1m | 2,950,000 | | New +2,950,000 | | [GREAT POINT PARTNERS LLC](/funds/1281446.md) | 2026-06-30 | $2.7m | 2,575,000 | | New +2,575,000 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.5m | 2,438,711 | | New +2,438,711 | | [Velan Capital Investment Management LP](/funds/1848809.md) | 2026-06-30 | $1.8m | 1,700,000 | | New +1,700,000 | | [Senvest Management, LLC](/funds/1328785.md) | 2026-06-30 | $1.3m | 1,230,895 | | Added +1,000,000 | ## Recent filings [All 500 filings](/companies/rntx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-04 | 16:31 ET | [8-K](/filings/0001193125-26-383726.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-383726 | | 2026-08-27 | 16:05 ET | [8-K](/filings/0001193125-26-371260.md) | 3.01 Delisting notice | 0001193125-26-371260 | | 2026-08-14 | 06:34 ET | [10-Q](/filings/0001193125-26-350270.md) | Quarterly report, period 2026-06-30 | 0001193125-26-350270 | | 2026-07-21 | 16:10 ET | [8-K](/filings/0001193125-26-310315.md) | 5.07 Shareholder vote results | 0001193125-26-310315 | | 2026-06-08 | 09:17 ET | [DEF 14A](/filings/0001193125-26-260809.md) | Proxy statement, period 2026-07-20 | 0001193125-26-260809 | | 2026-05-15 | 07:56 ET | [10-Q](/filings/0001193125-26-225352.md) | Quarterly report, period 2026-03-31 | 0001193125-26-225352 | | 2026-05-04 | 16:12 ET | [8-K](/filings/0001193125-26-204006.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-204006 | | 2026-04-28 | 17:29 ET | [S-1](/filings/0001193125-26-187803.md) | Registration statement | 0001193125-26-187803 | | 2026-04-27 | 06:51 ET | [10-K/A](/filings/0001193125-26-178787.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-178787 | | 2026-03-26 | 16:36 ET | [10-K](/filings/0001193125-26-126385.md) | Annual report, period 2025-12-31 | 0001193125-26-126385 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-126385.md), filed Mar 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8409ef25-3ce5-4211-aa24-d6de4d90f4e5) ## About the filer - CIK: 1420565 - Tickers: RNTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.